First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Strides is the first Indian company to get approval for the product.
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
The product will be manufactured at Lupin's facility in Nagpur, India.
The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.
Bisoprolol Fumarate Tablets are used to treat high blood pressure.
Merck’s first microbiology application and training lab in India
Better serving global partners and advancing healthcare innovation
Subscribe To Our Newsletter & Stay Updated
